Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Bondronat

Approved

STANDARD

Bondronat

Roche Diagnostics GmbH🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ca3a615afa074bd8
Company: Roche Diagnostics GmbH
Type: Standard

Approval Details

Approval Id: ca3a615afa074bd8
Drug Approval Philippines Name: Bondronat
Product Name: Bondronat
Registration Number: DR-XY31003
Brand Name: Bondronat
Generic Name: Ibandronic Acid
Dosage Form: Concentrate Solution For Iv Infusion
Dosage Strength: 6 mg/ 6 mL
Manufacturer: Roche Diagnostics GmbH
Importer: Roche (Philippines) Inc.
Distributor: Zuellig Pharma Corporation
Company Detail Path: /organization/roche-diagnostics-gmbh
Issuance Date: 24 July 2020
Expiry Date: 19 August 2025
Pharmacologic Category: Bisphosphonate
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ca3a615afa074bd8

Type

Standard

Back to Philippines FDA Approvals

Bondronat - Philippines FDA Drug Approval Details